Latigo Biotherapeutics, Inc.NASDAQ: LTGO

Latigo Biotherapeutics Ups IPO to 19.2 Million Shares

· Issued by Latigo Biotherapeutics, Inc.

Summary by 6ix AI

Latigo Biotherapeutics, a clinical-stage drug developer (its medicines are still being tested in people) working on non-opioid pain medicines, increased its initial public offering to 19.2 million shares at $18 each. It expects gross proceeds of $345.6 million.

Key details

  • Latigo previously planned to sell 16 million shares at between $16 and $18 each.
  • Underwriters have a 30-day option to buy up to an additional 2.88 million shares at the same price, minus discounts and commissions.
  • The shares are set to trade on the Nasdaq stock exchange under the symbol LTGO.
  • Latigo intends to use the proceeds to advance its clinical pipeline, including its lead product candidate LTG-001.

What’s still pending

  • The offering is expected to close on August 10.
  • Gross proceeds of $345.6 million are an expected figure.

6ix AI wrote this summary from the release below and checked it against the release.

By Katherine Hamilton

Latigo Biotherapeutics increased its initial public offering to 19.2 million shares for $18 apiece.

The clinical-stage biopharmaceutical company previously planned to sell 16 million shares at between $16 and $18 apiece.

Latigo now expects gross proceeds to be $345.6 million.

Underwriters also have a 30-day option to buy up to an additional 2.88 million shares at the same price, minus discounts and commissions.

The company, which develops non-opioid pain medicines, plans to trade on Nasdaq under the symbol LTGO. Trading is set to start Friday, with the offering to close Aug. 10.

It intends to use the proceeds from the offering to advance its clinical pipeline, including its lead product candidate LTG-001.

Write to Katherine Hamilton at [email protected]

Latigo Biotherapeutics, Inc. on 6ix

Later from Latigo Biotherapeutics

All Latigo Biotherapeutics news releases